Vertex Pharmaceuticals (VRTX)

Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, Gartner and Eli Lilly.

There's no guarantee that any stock will beat the market, but the chances look good for these three.

Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.

Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.

Market volatility could increase in the months ahead, but these stocks should hold up well.

Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.

Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.

There's more good news than bad news for this big biotech stock.

Vertex Pharmaceuticals (VRTX) offers strong growth, solid profitability, and reasonable valuations, making it a top pick for affordable growth investors.

A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red.

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop the development of VX-993 as a standalone treatment for acute pain. This setback in the company's drug pipeline overshadowed its recently reported strong second-quarter financial results. The news also compounded concerns after the company revealed that expanding the approval for another pain medicine, Journavx, also faced regulatory hurdles.

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.

The financial markets have been on a tumultuous ride in early August 2025, experiencing a dramatic "see-saw" pattern that has left investors both wary and hopeful. Following a sharp decline at the close of July, Wall Street staged a significant rebound on August 4th, largely propelled by robust gains in

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales.

Let's have a look at the S&P500 stocks with an unusual volume in today's session.

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.

Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.

Stay updated with the S&P500 stocks that are on the move in today's pre-market session.

The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.